Trial Profile
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of Oral FXR Modulator EYP001a Combined With Nucleos(t)Ide Analogues (NA) in Virologically Suppressed Chronic Hepatitis B Patients to Improve Functional Cure Rates
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2022
Price :
$35
*
At a glance
- Drugs Vonafexor (Primary) ; Entecavir; Tenofovir
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors ENYO Pharma
- 21 Sep 2022 Status changed from active, no longer recruiting to discontinued.
- 30 Jul 2021 Interim results presented in an ENYO Pharma media release.
- 30 Jul 2021 According to an ENYO Pharma media release, an interim analysis conducted by the DSMC concluded that Vonafexor was well tolerated and safe but there was no apparent efficacy benefit of Vonafexor with Entecavir. Therefore, no additional patients will be recruited in this study.